Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Stopped The rate of inclusion is too low to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives. The sponsor has decided to prematurely stop inclusions on January 13, 2022.

Conditions

• Venous Thromboembolism
• Lung Neoplasm

Interventions

• DRUG: Tinzaparin Sodium

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

• [object Object]
• [object Object]